Interim report
Page 1
Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 www.medanta.org, info@medanta.org, CIN: L85110DL2004PLC128319 Date: November 03, 2026 Ref:- GHL/2026-27/EXCH/70 The General Manager Dept. of Corporate Services BSE Limited, P J Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 543654 The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Symbol: MEDANTA Sub: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) Dear Sir(s), We would like to inform you that the Board of Directors of Global Health Limited (‘GHL/Company’) at its meeting held today i.e. Tuesday, November 03, 2026, has inter alia, approved the following: 1. Unaudited Standalone and Consolidated Financial Results of the Company for the Second Quarter & Half Year ended September 30, 2026 (‘Financial Results’). The certified copies of Results along with Limited Review Reports from the Statutory Auditors M/s Walker Chandiok & Co LLP, Chartered Accountants thereon, are enclosed herewith as Exhibit-I. Further, we hereby declare and confirm that the Statutory Auditors of the Company, have issued the Limited Review Reports with an unmodified opinion on the Unaudited Standalone and Consolidated Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2026 pursuant to the Listing Regulations. 2. The Project Budget of Rs. 997 Crores (including the cost of land) for construction of a 500 bedded hospital on the land parcel admeasuring 10560.36 sq. meters allotted by UP Housing & Development Board (UPAVP), at Siddharth Vihar Yojna, Ghaziabad, Uttar Pradesh . The details as required under Regulation 30 are enclosed as Annexure-A (in continuation of our earlier intimation in this regard dated September 28, 2026). Limited
Page 2
Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 www.medanta.org, info@medanta.org, CIN: L85110DL2004PLC128319 The Trading Window will open after 48 hours from the declaration of above Results, to the Stock Exchanges. The meeting of the Board of Directors commenced at 02:00 P.M. and concluded at 03:45 P.M. Thanking You, For Global Health Limited Rahul Ranjan Company Secretary & Compliance Officer M. No. A17035 Encl: a/a Limited
Page 3
Chartered Accountants Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune Walker Chandiok & Co LLP is registered with limited liability with identification number AAC- 2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India Independent Auditor’s Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Global Health Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results (‘the Statement’) of Global Health Limited (‘the Company’) which includes GHL Employee Welfare Trust (‘the Trust’) for the quarter ended 30 September 2026 and the year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (‘Listing Regulations’). 2. The Statement, which is the responsibility of the Company’s management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (‘Ind AS 34’), prescribed under section 133 of the Companies Act, 2013 (‘the Act’), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Walker Chandiok &._Co LLP Walker Chandiok & Co LLP 21st Floor, DLF Square Jacaranda Marg, DLF Phase II, Gurugram - 122 002 Haryana, India T +91 124 462 8099 F +91 124 462 8001
Page 4
Independent Auditor’s Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont’d) Chartered Accountants 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. Our conclusion is not modified in respect of this matter. For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013 Tarun Gupta Partner Membership No. 507892 UDIN: 26507892KTIZMA2964 Place: Gurugram Date: 03 November 2026 Walker Chandiok &_Co LLP
Page 5
S No. I II Ill IV V VI VII VIII IX X XI XII Glohel Health Limited R,iistered Off",a,: Medaab Medidiaic, E-111, Defence Colony, New Delhi - 110024, India Corporate Of'lke: Medaata- lloe Medicity, Sector- 311, Gurgaon, Haryana - 122001, India CIN:U51 I0DU004PLCl2S319 Tel: +91 124 483 4060; E-mail: compliaac:e@~org; Website: https://www.medanta.org Statement of standalone umadited fi---i reatts for the quarter and six months ended 30 Septtmber 2026 (' in millions, unl.ss otherwise stated) Qaa.-ended Six months ended Year ended Particulan 30 Septm,ber 2026 JOJ-2026 JO September 2025 30 September 2026 30 September 2025 31 March 2026 Umadited Uandited Umadited Unaudited Unaudited Audited Income Revenue from operations 12,080.94 10,787.23 9,264.28 22,868.17 18.085.84 37,093.78 Other income 258.89 240.60 228.00 499.49 459.39 1,064.08 T-lincome 12,33'-83 11,1127.83 9,492.28 23,367.66 111,545.23 311,157.86 Expemes Cost of materials conswned 2,446.15 2,261.59 2,032.16 4,707.74 3,953.79 7,858.56 Purchases of stock-in-trade 0.08 (0.44) 0.08 25.15 19.43 Changes in inventories of stock-in-trade 0.52 40.13 46.11 Employee benefits expense 3.013 97 2,854.73 2,483.33 5.868.70 4,812.78 9,892.59 Finance costs 170.65 158.90 88.83 329.55 145.41 410.85 Depreciation and amortisation expense 561.51 546.04 374.28 1,107.55 708.36 1.709.07 Retainers and consultants fee 1,750.81 1,659.19 1,282.33 3,410.00 2,375 14 5.445.32 Other expenses 1,965.90 1,716.28 1,540.65 3,682. 18 3 007.31 6,283.16 Total expenses 9,909.07 ,.196. 73 7,801.66 19,105.80 15,068.07 • 31,665.09 Profit befon exceptional itemo and tax 2,-00.76 1,831.10 1,690.62 4,261.86 3,477.16 6,492.77 Exceptional items (refer note 6) - (159.85) (355. 77) (377) Profit befon tax 2,-00 .76 1,831.10 1,850.47 4,261.86 3,832.93 6,496.54 Tax expenses Current tax 610.43 545.75 358.62 1,156.18 771.89 1,345.72 Tax pertaining to earlier years - - (33.30) Deferred tax charge/( credit) 7.74 (87.72) 89.86 (79.98) 139.41 222.11 Profit aflff tax 1.812.59 1.373.07 I 401.99 3 185.66 2.921.63 4-'162.01 Other comp1 ehensive income (i) Items that will not be reclassified to statcrn~ of profit or loss 35.12 (63.50) (10.67) (28.38) (7.66) 46.64 (ii) Equity instruments through OCI - (1.60) (iii) Income-tax relating to items that will not (8.84) 15.98 2.69 7.14 1.93 ( 11 .74) be reclassified to statement of profit or loss Total other comprehen!ive income 26.28 (47.52) (7.98) (21.24) 15.73) JJJO Total comprehensive income )Au.87 IJ25.55 IJ94.0I 3.164.42 2 915.90 4.995JI Paid-up equity share capital (face value off 537.35 537.54 537.58 537.35 537 58 537 38 2 each) Reserves (other equity) 39.588.28 Earnings per share (face value off 2 each) (not annualised for the quarters and six months) Basic (f per share) 6.75 5.11 5.22 11.85 10.87 18.46 Diluted(' per ahare) 6.73 5.10 5.22 11.83 10.85 18.42 Set accompanying note, to the ,tandalone unaud11ed financ,al ~n,/i,
Page 6
Global Health Limited CIN: L85110DL2004PLC128319 Note 1: Standalone balance shttt Hat 30 September 2026 (f in millions, unless otherwise: stated\ As at As at Particulars 30 September 2026 31 March 2026 Unaudited Audited ASSETS Property, plant and equipment 24,127.92 23,404.48 Right-of-use assets 6,306.49 5,489.10 Capital work-in-progress 1,987.93 1,197.01 Goodwill 52.16 Other intangible assets 126.15 137.85 Intangible assets under development - 0.59 Financial assets Investments 3,893.68 3,893.68 Loans 1,309.42 1,436.30 Other financial assets 912.15 1,047.92 Deferred tax assets (net) 130.17 43.06 Income-tax assets (net) 356.40 356.40 Other non-current assets 1,425.47 804.88 Total non-current Hsets 40,627.94 37,811.27 Current Hsets Inventories 546.71 508.97 Financial assets Trade receivables 4,881 .06 3,868.53 Cash and cash equivalents 2,045.27 959 .08 Bank balances other than cash and cash equivalents 10,982.28 9,804.50 Loans 133.33 103.55 Other financial assets 378.78 286.48 Other current assets 265.23 172.31 Total current Hsets 19,232.66 15,703.42 Total assets 59,860.60 53.514.69 EQUITY AND LIABILITIES Equity Equity share capital 537.35 537.38 Other equity 42,597.29 39,588.28 Total equity 43,134.64 40,125.66 Liabilities Non-current liabilities Financial liabilities Borrowings 5, 175.68 4,492.02 Lease 1 iabilities 2,892.44 2,048.62 Provisions 1,340.06 1,085.45 Other non-current liabilities 457.26 451.80 Total non-current liabilities 9,865.44 8,077.89 Current liabilities Financial liabilities Borrowings 254.92 87.05 Lease liabilities 283.60 198.90 Trade payables Total outstanding dues of micro enterprises and small enterprises 1,089.93 729.49 Total outstanding dues of creditors other than micro enterprises and small enterprises 1,538.28 1,291.41 Other financial liabilities 1,459.39 1, 198.52 Other current liabilities 1,590.53 1,515.04 Provisions 312.58 290.73 Current tax liabilities (net) 331.29 -Total current liabilities 6,860.52 5.311.14 Total equity and liabilities 59,860.60 53.514.69
Page 7
Global Health Limited CIN: L85110DL2004PLC128319 Note 2: Standalone Statement of Cash Flow for the period ntded JO Sq,tmtber 2026 (t m millions, unless otherwise stated) For the period ended For the period ended Particulars JO September 2026 JO September 2025 (Unaudited) <Unaudited) A CASH FLOWS FROM OPERA TING ACTIVITIES Profit before tax 4,261 .86 3,832.93 Adjustments for: Depreciation and amortisation expense 1, 107.55 708.36 Finance costs 329.55 145.41 Employee share based payment expense 120.10 171.44 Interest income (46548) (43669) Grant income (138 .01) (311 89) Loss allowance and bad debts written off 52.43 40.89 Advances written off (net) 0.06 - Unrealised foreign exchange (gain)/loss (net) (0 50) 6.85 Gain on sale of property, plant and equipments (net) (0 87) (0.33) Exceptional items - (355 77) Reversal for contingencies - (7 04) Operating profit before working capital changes 5,266.69 3,794.16 Movement in working capital: Trade receivables (1 ,06513) (754 10) Inventories (37 73) 5.25 Other assets (312 .02) (16513) Trade payables 605.29 446.76 Other liabilities 379.21 142.60 Provisions 248.08 (9()_ 76) Cash flo:ws from operating activities 5,084.39 3,378.78 Income-tax paid (net) (824.88) (76440) Net cash nows generated from operating activities (A) 4.259.51 2,614.38 B CASH FLOWS F_ROM INVESTING ACTIVITIES Purchase of property plant and equipments, capital work-in-progress and intangible assets (including capital (2,973.54) (3,592 .55) advances, capital creditors and deferred payment liabilities) Movement in other bank balances and deposits (net) (965 79) 4,142.11 Interest received 409 .39 438.27 Loans repayment from subsidiaries 97 09 79.55 Proceeds from disposal of property, plant and equipments 3.95 1.76 Payment for acquisition of leasehold land ( 128 71) Investment in subsidiary companies - ( 15 10) Net cash nows (used ln)/genented from investing activities (B) (3,428.90) 925.33 C CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from non-current borrowings 914.71 2.006.93 Repayment of non-current borrowings (62 50) Interest paid on borrowings (176.47) (95.32) Proceeds from issue of equity share capital (net of share issue expenses) 0.17 0.41 Purchase of treasury shares (142.35) -Dividend paid (99.23) -Payment of interest on lease payments (145 85) (104 .41) Principal elements of lease liabilities (32.90) (32.03) Premium for employee stock purchase shares to employees of subsidiary companies - 18.13 Net cash generated from financing activities (C) 255.58 1,793.71 Net increase in cash and cash equivalents (A+B+C) 1,086.19 5,333.42 Cash and cash equivalents at the beginning of the year 959.08 1,900.65 Cash and cash equivalents at the end of the period 2,045.27 7,234.07 Reconciliation of cash and cash equivalents as per statement of cash nm,, Balances with banks in current accounts 423.23 408.96 Cheques on hand 0.01 0.14 Cash on hand 27.03 21.36 Bank deposits with original maturity less than three months 1,595.00 6.803.61 2,045.27 7,234.07
Page 8
Global Health Limited Notes to the standalone unaudited financial results : 3 The above standalone unaudited financial results of Global Health Limited Cthe Company') , for the quarter and six months ended 30 September 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 03 November 2026 and a limited review of the !\llllle has been carried out by the statutory auditors . 4 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended). 5 The Chief Operating Decision Maker (CODM) examines the Company's performance from a service perspective and has identified the healthcare services as single business segment. 6 Ex.-.ntional items include: (t in millions) Particulars Quarter ended Six months ended Year ended 30 Seotember 2025 30 Seotem ber 2025 31 March 2026 Export Promotion Capital Goods (EPCG) Obligation (Refer point a be/aw) ( 195 92) (195 92) Stamp duty on merger (Refer point b below) ( 159 85) ( 159 85) ( I 59 85 ) Impact of new labour codes (Refer point c below) 352.00 Total (159.85) (355.77) (3.77) a During the six months ended 30 September 2025, the Company reversed interest liability on Export Promotion Capital Goods (EPCG) amounting to ? 195.92 millions. Pursuant to the filing of merger order with Registrar of Companies (ROC), the EPCG licenses have been transferred from Medanta Holdings Private Limited to the Company. The Company had achieved the required export obligation within the prescribed timeline. b Stamp duty was payable in connection with the merger of Medanta Holdings Private Limited with the Company, however during the quarter ended 30 September 2025, the Company reversed stamp duty amounting to ? 159.85 millions payable to Government of National Capital Territory of Delhi, pursuant to adjudication of its stamp duty application. c On 21 November 2025, the Government of India notified the four Labour Codes--namely, the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Occupational Safety, Health and Worlcing Cooditions Code, 2020----thereby consolidating 29 existing labour laws. The Company had evaluated and disclosed the incremental impact of these changes based on expert input and the best information available, in line with the guidance provided by the Institute of Chartered Accountants of India Given the material, regulatory-driven, and non-recurring nature of this impact, the Company had presented such incremental impact, aggregating to ,352 .00 millions under 'Exceptional items'. The Company continues to monitor the finalisation of the State Rules and any further government clarifications on other aspects of the Labour Codes. 7a The Company executed a Business Transfer Agreement (BT A) with Asian Institute of Oncology Private Limited for a 79 bedded Advanced Super Speciality Hospital primarily engaged in providing oncology services in Indore in April 2026. b. During the quarter ended 30 September 2026, the Company has been allotted under on line auction from UP Housing & Development Board ( UPA VP) a land parcel situated at Siddharth Vihar Yojna, Ghaziabad, Uttar Pradesh measuring 10560.36 sq. meters on free hold basis. Subsequent to the quarter ended 30 September 2026, the Board of Directors approved the proposed development of a 500-bedded hospital on the aforesaid land parcel. 8 Employee benefits expense include: Particulars Q,,artcr ended 30 September 20Ui JOJ11nc2026 30 September 2025 Employee share based payment exnensc 59.83 60.27 95.72 9 The standalone financial results also include the financial results ofGHL Employee Welfare Trust. Place : Gurugram Date : 03 November 2026 (i\~NDIQ~-<i P::o 1,ccr:.0 (t in millions) Six months ended Year ended 30 September 2026 30 September 2025 31 Much 2026 120.10 171.44 368.57
Page 9
Chartered Accountants Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune Walker Chandiok & Co LLP is registered with limited liability with identification number AAC- 2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India Independent Auditor’s Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Global Health Limited 1. We have reviewed the accompanying statement of consolidated unaudited financial results (‘the Statement’) of Global Health Limited (‘the Holding Company’) and its subsidiaries (the Holding Company and its subsidiaries together referred to as ‘the Group’), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 30 September 2026 and the consolidated year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (‘Listing Regulations’). 2. This Statement, which is the responsibility of the Holding Company’s management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (‘Ind AS 34’), prescribed under section 133 of the Companies Act, 2013 (‘the Act’), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Walker Chandiok &._Co LLP Walke r Chandiok & Co LLP 21st Floor, DLF Square Jacaranda Marg, DLF Phase II, Gurugram - 122 002 Haryana, India T +91 124 462 8099 F +91 124 462 8001
Page 10
Independent Auditor’s Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont’d) Chartered Accountants 4. Based on our review conducted , nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013 Tarun Gupta Partner Membership No. 507892 UDIN: 26507892DKCSRC2758 Place: Gurugram Date: 03 November 2026 Walker Chandiok &_Co LLP
Page 11
Independent Auditor’s Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont’d) Chartered Accountants Annexure 1 List of entities included in the Statement S. No. Name Relationship with the Holding Company 1 Global Health Patliputra Private Limited Wholly owned subsidiary 2 GHL Pharma & Diagnostic Private Limited Wholly owned subsidiary 3 GHL Hospital Limited Subsidiary 4 Global Health Institute of Medical Sciences Foundation Wholly owned subsidiary 5 Medanta Foundation- Poor and Needy Patients Welfare Trust Trust Walker Chandiok &_Co LLP
Page 12
S. No. I II lII IV V VI VII VD! IX X XI xn Global Health Limited Registered Office: MedUb Mecfodnoic, E-111, Drience Colony, New Delhi - 110024, India Corporate Office: Medallla - The Medici<y, Sector- 311, Gurgaon, Haryana - 122001, India CIN:USIIODU004PLC128319 Tel: +91 124 483 4060; E-mail: eo111pfsa~medanta.org; Web5ite: https:/lwww.medanta.org Statement of consolidated unaudited financial res.its for the quarter and six months ended 30 September 2026 Qaarter ended Six months ended Particulan 30 Septem hff 2026 JOJ .... 2026 30 September 2025 30 Septemhff 2026 30 Sept~ ber 2025 Unaaclited Unaaclited Unaudited Unaudited Unaudited Income Revenue from operations 14,690.43 13,040.51 10,992.80 27,730.94 21 ,301.24 Other income 236.15 221.64 196.68 457.79 401.18 Total income I ""26.511 13,262.15 11,189.48 211,18&.73 21,702.42 Expenses Cost of materials consumed 2,786.78 2,571.88 2,266.92 5,358.66 4,397.69 Purchases of stock-in-trade 458.15 407.32 287.84 865.47 605.74 Changes in inventories of stock-in-trade (32.36) (35.49) 0.80 (67.85) (57.30) Employee benefits expense 3,346.06 3,192.73 2,743.34 6,538 .79 5,307.38 Finance costs 280.85 266.76 171.12 547.61 308.97 Depreciation and amortisation expense 707.97 689.77 497.26 1,397.74 948.34 Retainers and consultants fee 2,130.11 2,007.26 1,549.45 4,137.37 2,916.45 Other expenses 2,300.75 2 029.29 1,834.46 4,330.04 3 551.37 Toal expenHS 11,971.31 11,129.52 9,351.19 23,107.83 17,978.64 Profit befon, exceptional items and tax 2,'US.27 2,132.63 1,838.29 5,080.90 3,723.78 Exceptional items (refer note 6) - (159.85) (355.77) Profit befon, tax 2,!MS.27 2,132.63 1,998.14 5,080.90 4,079.55 Tu expenses Current tax 642.90 545.75 358.62 1,188.65 771.89 Tax pertaining to earlier years - Deferred tax charge 113.93 14.36 55.52 128.29 133.84 Profit aflff tax 2.191.44 1 <n ~2 1 <lLl.00 3.763.96 3 173.82 Other comp1 ehensive income . (i) Items that will not be reclassified to statement of 34.74 (68.99) (12.34) (34.25) (9.23) profit or loss (ii) Equity instruments through OCI - (iii) Income-tax relating to items that will not be (8.74) 17.36 3. 11 8.62 2.33 reclassified to statement of profit or loss Total other comprehensive income 26.00 (51.63 (9.23 (25.63) (6.9()) Total comprehensive income 2,217.« 1,520.89 1,574.77 3,738Jl 3,166.92 Profit after tax attributable to: (i) Owners of the Holding Company 2.206.72 1,587.27 1,584.41 3,793.99 3. 174.50 (ii) Non-controlling interests (15.28) (14.75) (0.41) (30.03) (0.68) Other tomptthemive income attributable to: (i) Owners of the Holding Company 25.99 (51.62) (9.23) (25.63) (6.90) (ii) Non-controlling interests 0.01 (0.01) - - Toal comprehensive income attributable to: (i) Owners of the Holding Company 2,232.71 1,535.65 1,575.18 3,768.36 3,167.60 (ii) Non-controlling interests (15.27) (14.76) co:41) (30.03) (0.68) Paid-up equity share capital (face value oft 2 each) 537.35 537.54 537.58 537.35 537.58 Reserves ( other equity) Earnings per share (face value on 2 each) (not annualised for the quarters and six months) Buie (t per share) 8.21 5.91 5.89 14.12 11.81 Diluted<' ocr share) 8.20 5.90 5.89 14.09 11.79 See occompa,ryi,rg notes to the consolidated unaudited financial ns11/ts Year ended 31 Mardi 2026 Audited 44,102.66 985.94 45,08&.60 8.821.31 1,173.00 (26.30) 10,961.08 791.14 2,225.40 6,579.68 . 7,402.91 37"211-22 7,160.38 10.21 7,150.17 1,345.72 (33.30) 297.07 ~'Yll.63 50.86 (1.60) (128 1) 36.45 5,577. 13 5.564 60 (23 92) 36.44 0.01 5,601.04 (23.91) 537.38 39.078.32 20.71 20.66
Page 13
Global Health Limited CIN:L85110DL2004PLCl28319 Note I: Consolidated balance sheet as at 30 September 2026 Particulars ASSETS Non-current assen Property, plant and equipment Right-of-use assets Capital work-in-progress Goodwill Other intangible assets Intangible assets under development Financial assets Investments Other financial assets Deferred tax assets (net) Income-tax assets (net) Other non-current assets Total non-current a55ets Current asscn Inventories Financial assets Trade receivables Cash and cash equivalents Bank balances other than cash and cash equivalents Other financial assets Other current assets Total current assets Total assen EQUITY AND LIABILITIES Equity Equity share capital Other equity Non-controlling interests Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Other financial liabilities Provisions Deferred tax liabilities (net) Other non-current liabilities Total non-current liabilities Current liabilities Financial liabilities Borrowings Lease liabilities Trade payables Total outstanding dues of micro enterprises and small enterprises Total outstanding dues of creditors other than micro enterprises and small enterprises Other financial liabilities Other current liabilities Provisions Current tax liabilities (net) Total current liabilities Total eauitv and liabilities If in millions unless otherwise stated} As at As at 30 September 2026 31 March 2026 Unaudited 30,391.47 8,98337 2,065.89 52.16 144.73 0.98 25.50 992.70 186.99 516.54 1,815.39 45.175.72 883.22 5,223.24 2,962.41 11 ,046.06 432.11 338.91 20,885.95 66.061.67 53735 42,696.56 197.02 43,430.93 6,588.46 6.247.92 3.06 1,420.27 150.19 540.51 14.950.41 360.69 330.27 1,29031 1,811.71 1,555.56 1,677.68 322.82 331 .29 7,680.33 66 061.67 Audited 29,623.44 8, 163.70 1,322.05 160.46 1.57 25.50 1,116.88 156.46 554.78 1,176.00 42,300.84 789.83 4,111.85 1,273.33 10,028.95 321.59 223.65 16,749.20 59 050.04 537.38 39,078.32 227.05 39.842. 75 6,011.16 5.259.41 3.39 1, 139.21 - 522.81 12.935.98 299.59 330.30 879.25 1,544.45 1,332.28 1,585.57 299.87 - 6,271.31 59,050.04
Page 14
Global Haith Limited CIN:L85110DL2004PLC128319 Note 2: Consolidated statement of cash flow for the period ended 30 Sq,trmbtt 2026 Particulars A CASH FLOWS FROM OPERA TING ACTIVITIES Profit before tax Adjustments for: Depreciation and amortisation expense Finance costs Employee share based payment expense Grant income Interest income Loss allowance and bad debts written off (Reversal)/provision for contingencies Loss/(gain) on de-recognition of lease liabilities and right of use assets Exceptional items Gain on sale of property, plant and equipments (net) Liabilities written back Unrealised foreign exchange (gain)/loss (net) Operating profit before working capital changes Movement in working capital: Trade receivables Other assets Inventories Trade payables Other liabilities Provisions Cash flows from operating activities Income-tax paid (net) Net cash flows generated from operating activities (A) B CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property, plant and equipments , capital work-in-progress and intangible assets (including capital advances, capital creditors and deferred payment liabilities) Payment for acquisition of land Proceeds from disposal of property, plant and equipments Movement in other bank balances and deposits (net) Interest received Net cash flows (used in)/generated from investing activities (B) C CASH FWWS FROM FINANCING ACTIVITIES Proceeds from non-current borrowings Repayment of non-current borrowings Interest paid on borrowings Proceeds from issue of equity share capital to non-controlling interest Proceeds from issue of equity share capital (net of share issue expenses) Purchase of treasury shares Dividend paid Payment of interest on lease payments Principal elements oflease liabilities Net cash flows (used in)/generated from financing activities (C) Net increase in cash and cash equivalents (A+B+C) Cash and cash equivalents at the beginning of the year Cash and cash equivalents at the end of the period Reconciliation of cash and cash equivalents u per statrment of ash flow Balances with banks in current accounts Cheques on hand Cash on hand Bank deposits with original maturity less than three months (fin millions unless otherwise stated) For the period ended For the period ended 30 September 2026 30 September 2025 Unaudited Unaudited 5,080.90 4,079.55 1,397.74 948.34 547.61 308.97 126.49 178.81 (142.23) (312.48) (425 20) (377 93) 41.61 40.14 (7 04) 1.24 ( 1.81) . (35577) (0.98) (0 33) (004) (7.43) 1608 6,619.71 4,516.53 (1 , 153.17) (77129) (242.64) (205.03) (93.39) (61.17) 678.36 555.77 413.10 153.60 269.76 (86.25) 6,491.73 4,102.16 (813.61) (816.87) 5.678.12 3.2ll'i.29 (3,39138) (4,127 11) ( 128 71 l 6.27 2.51 (804.74) 4,338.88 360.45 37905 13.829.40 464.62 913.85 2,006 79 (274.77) (49.55) (231.96) (173.78) . 15.00 0.17 0.41 (142.35) . (99.23) (240.71) (194 72) (8464) (6422) (159.64) L'i39.93 1,689.08 5,289.84 I 273.33 2 302.00 2.962.41 7.591.84 518.64 463.37 0.01 0.14 36.59 30.40 2407 .17 7 097.93 2 962.41 7.591.84
Page 15
Global Health Limited Notes to the consolidated unaudited financial mu Its: 3 The above consolidated unaudited financial results of Global Health Limited Cthe Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred as 'the Group'), for the quarter and six months ended 30 Septembc- 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 03 November 2026 and a limited review of the same has been carried out by the statutory auditors. 4 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended). 5 The Chief Operating Decision Maker (CODM) examines the Group's performance from. a service perspective and has identified the healthcare services as single business segment. 6 Exceotional items include: (f in millions) Particulan Quarter ended Six months ended Year ended 30 Septem her 2025 30 Seotem her 2025 31 Mardi 2026 Export Promotion Capital Goods (EPCG) Obligation - (195.92) (195.92) (Refer ooint a below) Stamp duty on merger (Refer point b be/aw) (159.85) (159.85) (159.85) Impact of new Labour Codes 365.98 (Refer point c below) - - Total (159.85 (355.77) 10.21 a During the six months ended 30 September 2025, the Holding Company reversed interest liability on Export Promotion Capital Goods (EPCG) amounting to~ 195.92 millions. Pursuant to the filing of merger order with Registrar of Companies (ROC), the EPCG licenses have been transferred from Medanta Holdings Private Limited to the Holding Company. The Holding Company had achieved the required export obligation within the prescribed timeline. b Stamp duty was payable in connection with the merger of Medanta Holdings Private Limited with the Holding Company, however during the quarter ended 30 September 2025, the Holding Company reversed stamp duty amounting to ~ 159.85 millions payable to Government of National Capital Territory of Delhi, pursuant to adjudication of its stamp duty application. c On 21 November 2025, the Government of India notified the four Labour Codes-namely, the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020---thereby consolidating 29 existing labour laws. To facilitate the assessment of the financial impact arising from these regulatory changes, the Ministry of Labour & Employment issued Central Rules and related FAQs The Group had evaluated and disclosed the incremental impact of these changes based on expert input and the best information available, in line with the guidance provided by the Institute of Chartered Accountants of India. Given the material, regulatory-driven, and non-recurring nature of this impact, the Group had presented such incremental impact, aggregating to l!:365.98 millions under 'Exceptional items' The Group continues to monitor the finalisation of the State Rules and any further government clarifications on other aspects of the Labour Codes. 7a The Holding Company executed a Business Transfer Agreement (BT A) with Asian Institute of Oncology Private Limited for a 79 bedded Advanced Super Speciality Hospital primarily engaged in providing oncology services in Indore in April 2026. b During the quarter ended 30 September 2026, the Holding Company has been allotted under online auction from UP Housing & Development Board (UPA VP) a land parcel situated at Siddharth Vihar Vojna. Ghaziabad, Uttar Pradesh measuring I 0560.36 sq. meters on free hold basis. Subsequent to the quarter ended 30 September 2026, the Board of Directors approved the proposed development of a 500-bedded hospital on the aforesaid land parcel. 8 Employee benefits expense include: (f in millions) Particulan Q,,artff eaded Six months ended Year ended 30 September 2026 I 30Jane2026 I 30 September 2025 30 September 2026 I 30 September 2025 31 March 2026 Emolovee share based oavment exoense 62.881 63.611 100.04 126.491 178.81 382.98 9 Previous period figures have been regrouped/reclassified to conform to the current period's classification. For and on behalf of the Board of Directors of Global Health Limited Place : Gurugram Date : 03 November 2026 Dr. Naresh Trehan \..--Chairman and Managing Director
Page 16
Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 www.medanta.org, info@medanta.org, CIN: L85110DL2004PLC128319 Annexure A Disclosure pursuant to Regulation 30 of SEBI Listing Regulations read with relevant SEBI Circular(s) S. No. Particulars Information Required 1. Existing capacity As on September 30, 2026, Medanta has existing capacity of 3,811 beds. 2. Existing capacity utilization Currently, Medanta Hospitals are operating in Gurugram, Indore, Ranchi, Lucknow, Patna and Noida. 3. Proposed capacity addition The Land Parcel allows construction of 500 bedded multi- specialty Hospital (as against initial assessment of 350 beds with proposal to acquire additional FSI). 4. Period within which the proposed capacity is to be added The proposed capacity will be added over the next 3 -4 years in a phased manner. 5. Investment required Land purchase cost is Rs. 165.82 crores. The estimated project cost including land is of Rs. 997 crores. 6. Mode of financing Purchase of Land Parcel is proposed to be funded through Internal accruals while funding for the entire project will be through a mix of internal accruals and debt. 7. Rationale Ghaziabad presents a compelling healthcare investment opportunity, underpinned by a large and expanding population, accelerating urbanisation, sustained residential and commercial development, and strong connectivity with the Delhi -NCR region. The city also functions as a significant referral catchment for east Delhi, Meerut, Saharanpur, Hapur, Bulandshahr and the broader western Uttar Pradesh belt. The proposed site at Siddharth Vihar offers a strategically positioned location for a large-scale integrated healthcare facility in one of the city’s fastest -developing micro - markets. The project would enable the Company to address growing demand for advanced medical care while leveraging its established clinical expertise, brand equity, technology capabilities, medical talent and existing healthcare ecosystem. Limited